FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
US5061620A
(en)
|
1990-03-30 |
1991-10-29 |
Systemix, Inc. |
Human hematopoietic stem cell
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
AU2764792A
(en)
|
1991-10-04 |
1993-05-03 |
Iit Research Institute |
Conversion of plastic waste to useful oils
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
JP4157160B2
(ja)
|
1991-12-13 |
2008-09-24 |
ゾーマ テクノロジー リミテッド |
改変抗体可変領域の調製のための方法
|
WO1994004678A1
(en)
|
1992-08-21 |
1994-03-03 |
Casterman Cecile |
Immunoglobulins devoid of light chains
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
NZ258392A
(en)
|
1992-11-13 |
1997-09-22 |
Idec Pharma Corp |
Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
|
HU221001B1
(hu)
|
1994-03-17 |
2002-07-29 |
Merck Patent Gmbh. |
Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US5773292A
(en)
|
1995-06-05 |
1998-06-30 |
Cornell University |
Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
ES2176574T3
(es)
|
1996-09-03 |
2002-12-01 |
Gsf Forschungszentrum Umwelt |
Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
|
NZ334691A
(en)
|
1996-10-11 |
2000-12-22 |
Bristol Myers Squibb Co |
Compositions of anti-4-1BB antibody effective for immunomodulation and treatment of T-cell autoimmune disease
|
CN1203178C
(zh)
|
1997-10-27 |
2005-05-25 |
尤尼利弗公司 |
多价抗原结合蛋白
|
AU3596599A
(en)
|
1998-01-26 |
1999-08-09 |
Unilever Plc |
Method for producing antibody fragments
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
AU2291700A
(en)
|
1999-01-19 |
2000-08-07 |
Unilever Plc |
Method for producing antibody fragments
|
JP4896327B2
(ja)
|
1999-08-23 |
2012-03-14 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
Pd−1、b7−4の受容体、およびその使用
|
EP1792991A1
(en)
|
1999-08-24 |
2007-06-06 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
EP1223980B1
(de)
|
1999-10-28 |
2003-05-21 |
Hofbauer, Reinhold |
Verwendung von csf-1-inhibitoren
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
US20060228364A1
(en)
|
1999-12-24 |
2006-10-12 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
US7034121B2
(en)
|
2000-01-27 |
2006-04-25 |
Genetics Institue, Llc |
Antibodies against CTLA4
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
DK1257632T3
(da)
|
2000-02-24 |
2008-01-28 |
Xcyte Therapies Inc |
Samtidig stimulering og opkoncentrering af celler
|
CA2408617A1
(en)
|
2000-05-12 |
2001-11-22 |
Amgen Inc. |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
WO2001090190A2
(en)
|
2000-05-26 |
2001-11-29 |
National Research Council Of Canada |
Single-domain antigen-binding antibody fragments derived from llama antibodies
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
GB0100621D0
(en)
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VI
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
CN1195779C
(zh)
|
2001-05-24 |
2005-04-06 |
中国科学院遗传与发育生物学研究所 |
抗人卵巢癌抗人cd3双特异性抗体
|
US7666414B2
(en)
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
CN100497389C
(zh)
|
2001-06-13 |
2009-06-10 |
根马布股份公司 |
表皮生长因子受体(egfr)的人单克隆抗体
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
US7371849B2
(en)
|
2001-09-13 |
2008-05-13 |
Institute For Antibodies Co., Ltd. |
Methods of constructing camel antibody libraries
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
JP5355839B2
(ja)
|
2001-10-23 |
2013-11-27 |
ピーエスエムエー デベロプメント カンパニー, エル.エル.シー. |
Psma抗体およびタンパク質マルチマー
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
CN1652821A
(zh)
|
2002-01-28 |
2005-08-10 |
米德列斯公司 |
抗前列腺特异性膜抗原(psma)的人单克隆抗体
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
EP1507556B1
(en)
|
2002-05-02 |
2016-07-27 |
Wyeth Holdings LLC |
Calicheamicin derivative-carrier conjugates
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
DE60305919T2
(de)
|
2002-06-28 |
2007-01-18 |
Domantis Limited, Cambridge |
Dual-specifische liganden mit erhöhter halbwertszeit
|
PL375144A1
(en)
|
2002-07-30 |
2005-11-28 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
EP3284753B1
(en)
|
2002-10-17 |
2019-06-05 |
Genmab A/S |
Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis
|
CN1795009B
(zh)
|
2002-11-07 |
2014-07-09 |
伊谬诺金公司 |
抗-cd33抗体及其用途
|
WO2004042404A1
(en)
|
2002-11-07 |
2004-05-21 |
Erasmus Universiteit Rotterdam |
Fret probes and methods for detecting interacting molecules
|
WO2004041865A2
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Stabilized single domain antibodies
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
ES2466716T3
(es)
|
2002-11-08 |
2014-06-11 |
Ablynx N.V. |
Anticuerpos de un solo dominio estabilizados
|
AU2003286004A1
(en)
|
2002-11-08 |
2004-06-07 |
Ablynx N.V. |
Single domain antibodies directed against interferon- gamma and uses therefor
|
GB0228210D0
(en)
|
2002-12-03 |
2003-01-08 |
Babraham Inst |
Single chain antibodies
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
AU2004242845B2
(en)
|
2003-05-31 |
2011-06-02 |
Amgen Research (Munich) Gmbh |
Human-anti-human CD3 binding molecules
|
EP1638510B1
(en)
|
2003-07-01 |
2015-09-02 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
MXPA05013923A
(es)
|
2003-07-02 |
2006-08-11 |
Univ Genova |
Anticuerpos nk receptores de pan-kir2dl y su utilizacion en diagnostico y terapia.
|
KR20060038461A
(ko)
|
2003-07-24 |
2006-05-03 |
이나뜨 파르마 |
Nk 세포 강화 화합물을 사용하여 치료용 항체의 효율을높이는 방법 및 조성물
|
CA2536238C
(en)
|
2003-08-18 |
2015-04-07 |
Medimmune, Inc. |
Humanization of antibodies
|
US20050042664A1
(en)
|
2003-08-22 |
2005-02-24 |
Medimmune, Inc. |
Humanization of antibodies
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
NZ546173A
(en)
|
2003-10-16 |
2009-04-30 |
Micromet Ag |
Multispecific deimmunized CD3-binders
|
CN100376599C
(zh)
|
2004-04-01 |
2008-03-26 |
北京安波特基因工程技术有限公司 |
基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
|
JP5070045B2
(ja)
|
2004-05-27 |
2012-11-07 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
新規人工抗原提示細胞およびそれらの用途
|
US8921528B2
(en)
|
2004-06-01 |
2014-12-30 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
US20080069772A1
(en)
|
2004-08-26 |
2008-03-20 |
Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum |
Treatment of transformed or infected biological cells
|
EP1634603A1
(de)
|
2004-08-26 |
2006-03-15 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Behandlung von transformierten oder infizierten biologischen Zellen
|
FR2879605B1
(fr)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
DE602006003695D1
(de)
|
2005-01-05 |
2009-01-02 |
F Star Biotech Forsch & Entw |
Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
PT1836225E
(pt)
|
2005-01-06 |
2012-01-10 |
Novo Nordisk As |
Agentes de ligação a kir e métodos de utilização dos mesmos
|
PT1866339E
(pt)
|
2005-03-25 |
2013-09-03 |
Gitr Inc |
Moléculas de ligação a gitr e suas utilizações
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
US20060252096A1
(en)
|
2005-04-26 |
2006-11-09 |
Glycofi, Inc. |
Single chain antibody with cleavable linker
|
CN101213297B
(zh)
|
2005-05-09 |
2013-02-13 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
|
EP2365000A3
(en)
|
2005-05-18 |
2013-01-16 |
Ablynx N.V. |
Improved nanobodiesTM against tumor necrosis factor-alpha
|
PL3415535T3
(pl)
|
2005-05-20 |
2021-06-14 |
Ablynx N.V. |
Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
KR101411165B1
(ko)
|
2005-07-01 |
2014-06-25 |
메다렉스, 엘.엘.시. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
|
BRPI0615026A8
(pt)
|
2005-08-19 |
2018-03-06 |
Abbott Lab |
imunoglobulina de domínio variável duplo e seus usos
|
AU2006301492B2
(en)
|
2005-10-11 |
2011-06-09 |
Amgen Research (Munich) Gmbh |
Compositions comprising cross-species-specific antibodies and uses thereof
|
WO2007042573A2
(en)
|
2005-10-14 |
2007-04-19 |
Innate Pharma |
Compositions and methods for treating proliferative disorders
|
GB0521991D0
(en)
|
2005-10-28 |
2005-12-07 |
Univ Dundee |
Siglec-9 binding agents
|
JP2009515878A
(ja)
|
2005-11-12 |
2009-04-16 |
イーライ リリー アンド カンパニー |
抗egfr抗体
|
WO2007062466A1
(en)
|
2005-11-29 |
2007-06-07 |
The University Of Sydney |
Demibodies: dimerisation-activated therapeutic agents
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
US20110038854A1
(en)
|
2006-03-30 |
2011-02-17 |
University Of Medicine And Dentistry Of New Jersey |
Strategy for homo- or hetero-dimerization of various proteins in solution and in cell
|
EP2007423A2
(en)
|
2006-04-05 |
2008-12-31 |
Pfizer Products Incorporated |
Ctla4 antibody combination therapy
|
US20070269422A1
(en)
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
AU2007285695B2
(en)
|
2006-08-18 |
2012-05-24 |
Ablynx N.V. |
Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
|
CA2663042A1
(en)
|
2006-09-08 |
2008-03-13 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
CN101557817A
(zh)
*
|
2006-09-14 |
2009-10-14 |
人类基因科学公司 |
清蛋白融合蛋白
|
US20100166734A1
(en)
|
2006-12-20 |
2010-07-01 |
Edward Dolk |
Oral delivery of polypeptides
|
CA2675291C
(en)
|
2007-01-11 |
2017-05-23 |
Novo Nordisk A/S |
Killer ig-like receptor (kir) antibodies, formulations, and uses thereof
|
PT2520590T
(pt)
|
2007-04-03 |
2018-11-14 |
Amgen Res Munich Gmbh |
Domínio de ligação específico de espécies cruzadas
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトgitr抗体による免疫制御の解除とその応用
|
CA2687903C
(en)
|
2007-05-24 |
2016-09-13 |
Ablynx N.V. |
Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 pd-1에 대한 항체
|
EP2014680A1
(en)
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
JP5932217B2
(ja)
|
2007-07-12 |
2016-06-08 |
ジーアイティーアール, インコーポレイテッド |
Gitr結合分子を使用する併用療法
|
US9040666B2
(en)
|
2007-07-13 |
2015-05-26 |
Bac Ip B.V. |
Single-domain antigen-binding proteins that bind mammalian IgG
|
EP3492488A1
(en)
|
2007-08-22 |
2019-06-05 |
The Regents of The University of California |
Activatable binding polypeptides and methods of identification and use thereof
|
CA2698419C
(en)
|
2007-09-07 |
2019-11-12 |
Edward Dolk |
Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
ES2622460T3
(es)
|
2007-09-26 |
2017-07-06 |
Ucb Biopharma Sprl |
Fusiones de anticuerpos con doble especificidad
|
MX2010007935A
(es)
|
2008-01-24 |
2010-08-23 |
Novo Nordisk As |
Anticuerpo monoclonal humanizado anti-nkg2a humano.
|
HUE034465T2
(en)
|
2008-02-11 |
2018-02-28 |
Cure Tech Ltd |
Monoclonal antibodies for tumor treatment
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
ES2713864T3
(es)
|
2008-06-05 |
2019-05-24 |
Ablynx Nv |
Secuencias de aminoácidos dirigidas contra proteínas de la envuelta de un virus y polipéptidos que comprenden las mismas para el tratamiento de enfermedades virales
|
US20100122358A1
(en)
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
KR20110044992A
(ko)
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
TGF-β 길항제 다중-표적 결합 단백질
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
DE102008036127A1
(de)
|
2008-08-01 |
2010-02-04 |
Emitec Gesellschaft Für Emissionstechnologie Mbh |
Verfahren zum Betrieb einer Abgasanlage mit Lambda-Regelung
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
CN102203125A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
NZ591130A
(en)
|
2008-08-25 |
2012-09-28 |
Amplimmune Inc |
Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
|
EP2352763B2
(en)
|
2008-10-01 |
2022-09-21 |
Amgen Research (Munich) GmbH |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
CA2738565C
(en)
|
2008-10-01 |
2023-10-10 |
Micromet Ag |
Cross-species-specific psmaxcd3 bispecific single chain antibody
|
EP2352765B1
(en)
|
2008-10-01 |
2018-01-03 |
Amgen Research (Munich) GmbH |
Cross-species-specific single domain bispecific single chain antibody
|
EP2337798A4
(en)
|
2008-10-14 |
2012-10-24 |
Ca Nat Research Council |
BSA-SPECIFIC ANTIBODIES
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
WO2010077643A1
(en)
|
2008-12-08 |
2010-07-08 |
Tegopharm Corporation |
Masking ligands for reversible inhibition of multivalent compounds
|
PE20120341A1
(es)
|
2008-12-09 |
2012-04-24 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
EP2210902A1
(en)
|
2009-01-14 |
2010-07-28 |
TcL Pharma |
Recombinant monovalent antibodies
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
RU2015132478A
(ru)
|
2009-03-05 |
2015-12-10 |
Эббви Инк. |
Связывающие il-17 белки
|
WO2011028683A1
(en)
|
2009-09-03 |
2011-03-10 |
Schering Corporation |
Anti-gitr antibodies
|
US20110195494A1
(en)
|
2009-10-02 |
2011-08-11 |
Boehringer Ingelheim International Gmbh |
Dll4-binging molecules
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
BR112012012983A2
(pt)
|
2009-12-04 |
2020-09-15 |
Genentech Inc |
método para sintetizar um anticorpo multiespecífico, método para sintetizar um painel de anticorpos multiespecíficos, método para sintetizar um análogo de anticorpo, método para sintetizar um painel de análogos de anticorpo e composições
|
EP2332994A1
(en)
|
2009-12-09 |
2011-06-15 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Trispecific therapeutics against acute myeloid leukaemia
|
CN102791738B
(zh)
|
2009-12-10 |
2015-10-07 |
霍夫曼-拉罗奇有限公司 |
优先结合人csf1r胞外域4的抗体及其用途
|
ME02505B
(me)
|
2009-12-29 |
2017-02-20 |
Aptevo Res & Development Llc |
Heterodimerni vezujući proteini i njihove upotrebe
|
GB2476681B
(en)
|
2010-01-04 |
2012-04-04 |
Argen X Bv |
Humanized camelid VH, VK and VL immunoglobulin domains
|
HUE056313T2
(hu)
*
|
2010-01-29 |
2022-02-28 |
Chugai Pharmaceutical Co Ltd |
Anti-DLL3 antitest
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 csf-1r에 대한 항체 및 이의 용도
|
WO2011131407A1
(en)
|
2010-03-05 |
2011-10-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
EP2550529B1
(en)
|
2010-03-23 |
2021-11-17 |
Iogenetics, LLC. |
Bioinformatic processes for determination of peptide binding
|
WO2011117423A1
(en)
|
2010-03-26 |
2011-09-29 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against cxcr7
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
JP6008842B2
(ja)
|
2010-05-04 |
2016-10-19 |
ファイブ プライム セラピューティックス インコーポレイテッド |
Csf1rに結合する抗体
|
TWI629483B
(zh)
|
2010-06-11 |
2018-07-11 |
協和醱酵麒麟有限公司 |
anti-TIM-3 antibody
|
CN105734678B
(zh)
|
2010-07-16 |
2019-11-05 |
阿迪马布有限责任公司 |
合成多核苷酸文库
|
JP2013540701A
(ja)
|
2010-08-12 |
2013-11-07 |
セラクローン サイエンシーズ, インコーポレイテッド |
抗赤血球凝集素抗体組成物およびその使用方法
|
KR101612999B1
(ko)
|
2010-08-24 |
2016-04-15 |
로슈 글리카트 아게 |
활성화가능 이중특이적 항체
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
WO2012042026A1
(en)
|
2010-09-30 |
2012-04-05 |
Ablynx Nv |
Biological materials related to c-met
|
US20130273055A1
(en)
|
2010-11-16 |
2013-10-17 |
Eric Borges |
Agents and methods for treating diseases that correlate with bcma expression
|
AR083957A1
(es)
|
2010-11-22 |
2013-04-10 |
Innate Pharma Sa |
Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
|
CN103476943A
(zh)
|
2011-03-10 |
2013-12-25 |
普罗维克图斯药品公司 |
用于增强治疗癌症的局部和全身性免疫调节疗法的组合
|
US9029113B2
(en)
|
2011-03-11 |
2015-05-12 |
Kaneka Corporation |
Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same
|
KR20140018299A
(ko)
|
2011-03-30 |
2014-02-12 |
아블린쓰 엔.브이. |
Tnf-알파에 대한 단일 도메인 항체를 이용하여 면역 장애를 치료하는 방법
|
IL285335B2
(en)
|
2011-04-08 |
2023-12-01 |
Us Health |
Chimeric antigen receptors against epidermal growth factor receptor variant III and their use in cancer treatment
|
SI2699264T1
(en)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind B7-H1 and PD-1
|
CN103842383B
(zh)
*
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
AU2012260601B2
(en)
|
2011-05-25 |
2018-02-01 |
Innate Pharma, S.A. |
Anti-KIR antibodies for the treatment of inflammatory disorders
|
DK3415531T3
(da)
|
2011-05-27 |
2023-09-18 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17)-bindende proteiner
|
ES2759936T3
(es)
|
2011-06-23 |
2020-05-12 |
Ablynx Nv |
Proteínas de unión a albúmina sérica
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
WO2013036130A1
(en)
|
2011-09-09 |
2013-03-14 |
Universiteit Utrecht Holding B.V. |
Broadly neutralizing vhh against hiv-1
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
US20140220017A1
(en)
|
2011-09-23 |
2014-08-07 |
Universitat Stuttgart |
Serum half-life extension using igbd
|
CN106046161B
(zh)
|
2011-09-30 |
2019-09-13 |
埃博灵克斯股份有限公司 |
与C-Met相关的生物物质
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
RS61033B1
(sr)
|
2011-11-28 |
2020-12-31 |
Merck Patent Gmbh |
Antitela na pd-l1 i njihova upotreba
|
US10023643B2
(en)
|
2011-12-15 |
2018-07-17 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R and uses thereof
|
AU2012351728A1
(en)
|
2011-12-16 |
2014-06-19 |
Oncology Institute Of Southern Switzerland |
Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
|
LT2802607T
(lt)
|
2012-01-13 |
2018-02-12 |
Julius-Maximilians-Universität Würzburg |
Dviguba antigeno indukuota dvišalė funkcinė komplementacija
|
EP2807189B1
(en)
|
2012-01-23 |
2019-03-20 |
Ablynx N.V. |
Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
|
CN104093740B
(zh)
|
2012-02-06 |
2018-01-09 |
弗·哈夫曼-拉罗切有限公司 |
使用csf1r抑制剂的组合物和方法
|
EA201491572A1
(ru)
|
2012-02-22 |
2014-12-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиции и способы получения устойчивой популяции t-клеток, используемых для лечения злокачественного новообразования
|
WO2013126746A2
(en)
*
|
2012-02-24 |
2013-08-29 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
WO2013128027A1
(en)
|
2012-03-01 |
2013-09-06 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
CN107266574A
(zh)
|
2012-03-30 |
2017-10-20 |
拜尔健康护理有限责任公司 |
蛋白酶调节的抗体
|
CA2870545A1
(en)
|
2012-04-20 |
2013-10-24 |
Emergent Product Development Seattle, Llc |
Cd3 binding polypeptides
|
RU2670743C9
(ru)
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
BR122022015975B1
(pt)
|
2012-05-15 |
2024-01-02 |
Bristol-Myers Squibb Company |
Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo
|
KR101566538B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th17 세포 전환용 에피토프 및 이의 용도
|
WO2013192546A1
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and mehtods of using the same
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
WO2014012085A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Bispecific asymmetric heterodimers comprising anti-cd3 constructs
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
EP2890709A2
(en)
|
2012-08-31 |
2015-07-08 |
arGEN-X N.V. |
Highly diverse combinatorial antibody libraries
|
SG10201906328RA
(en)
|
2012-08-31 |
2019-08-27 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
KR101963231B1
(ko)
|
2012-09-11 |
2019-03-28 |
삼성전자주식회사 |
이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
WO2014052064A1
(en)
|
2012-09-27 |
2014-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
NZ631405A
(en)
|
2012-10-02 |
2017-01-27 |
Bristol Myers Squibb Co |
Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
|
US9243058B2
(en)
|
2012-12-07 |
2016-01-26 |
Amgen, Inc. |
BCMA antigen binding proteins
|
ES2755156T3
(es)
|
2012-12-17 |
2020-04-21 |
Trillium Therapeutics Inc |
Tratamiento de células enfermas CD47+ con fusiones SIRP alfa-Fc
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
GB201302447D0
(en)
*
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
AU2014222509A1
(en)
|
2013-02-28 |
2015-10-01 |
University Court Of The University Of Edinburgh |
CSF1 therapeutics
|
EP3447072A3
(en)
|
2013-03-05 |
2019-05-22 |
Baylor College of Medicine |
Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
|
CA2906587C
(en)
|
2013-03-13 |
2023-02-14 |
Health Research, Inc. |
Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
|
US10351626B2
(en)
|
2013-03-14 |
2019-07-16 |
The Scripps Research Institute |
Targeting agent antibody conjugates and uses thereof
|
WO2014159915A1
(en)
|
2013-03-14 |
2014-10-02 |
The Board Of Regents Of The University Of Texas System |
Her3 specific monoclonal antibodies for diagnostic and therapeutic use
|
ES2753950T3
(es)
*
|
2013-03-15 |
2020-04-15 |
Amgen Res Munich Gmbh |
Moléculas de unión monocatenarias que comprenden ABP del extremo N
|
AR095502A1
(es)
|
2013-03-15 |
2015-10-21 |
Bayer Healthcare Llc |
Anticuerpos profármaco contra el inhibidor de la vía del factor tisular
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
EP2970484B2
(en)
|
2013-03-15 |
2022-09-21 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
AU2014274215B2
(en)
|
2013-05-28 |
2019-02-28 |
Dcb-Usa Llc |
Antibody locker for the inactivation of protein drug
|
WO2015013671A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
KR102362609B1
(ko)
|
2013-08-01 |
2022-02-11 |
위니베르시트카솔리끄드루뱅 |
항garp 단백질 항체와 그 용도
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
MX2016003292A
(es)
|
2013-09-13 |
2016-06-24 |
Beigene Ltd |
Anticuerpos anti-muerte programada 1 y su uso como terapeuticos y diagnosticos.
|
BR122023024195A2
(pt)
|
2013-09-20 |
2023-12-26 |
Bristol-Myers Squibb Company |
Usos de anticorpos anti-lag-3 e anticorpos anti-pd-1
|
MX2016003942A
(es)
|
2013-09-24 |
2016-10-03 |
Univ Washington Through Its Center For Commercialization |
Proteinas de union a desmogelina 2 (dsg2) y usos de los mismos.
|
EP3049439B1
(en)
|
2013-09-26 |
2019-12-25 |
Ablynx N.V. |
Bispecific nanobodies
|
US20160263087A1
(en)
|
2013-11-08 |
2016-09-15 |
Iteos Therapeutics |
Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
|
US9126984B2
(en)
|
2013-11-08 |
2015-09-08 |
Iteos Therapeutics |
4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
|
WO2015082499A2
(en)
|
2013-12-03 |
2015-06-11 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
CN106459182B
(zh)
|
2013-12-30 |
2021-09-03 |
岸迈生物科技有限公司 |
串联fab免疫球蛋白及其用途
|
EP3105225A1
(en)
|
2014-02-12 |
2016-12-21 |
iTeos Therapeutics |
Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
WO2015140717A1
(en)
|
2014-03-18 |
2015-09-24 |
Iteos Therapeutics |
Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
CN107172880B
(zh)
|
2014-03-24 |
2021-09-28 |
癌症研究技术有限公司 |
含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
|
WO2015146437A1
(ja)
|
2014-03-25 |
2015-10-01 |
国立大学法人東北大学 |
高機能性IgG2型二重特異性抗体
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
MX2016012984A
(es)
|
2014-04-04 |
2017-05-09 |
Iomet Pharma Ltd |
Derivados indol para uso en medicina.
|
WO2015168643A2
(en)
|
2014-05-02 |
2015-11-05 |
Momenta Pharmaceuticals, Inc. |
Compositions and methods related to engineered fc constructs
|
MX2016015005A
(es)
|
2014-05-15 |
2017-09-28 |
Iteos Therapeutics |
Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1.
|
PL3148579T3
(pl)
|
2014-05-28 |
2021-07-19 |
Agenus Inc. |
Przeciwciała anty-gitr i sposoby ich zastosowania
|
RU2718692C2
(ru)
|
2014-05-29 |
2020-04-13 |
Мэкроудженикс, Инк. |
Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
|
SI3151921T1
(sl)
|
2014-06-06 |
2019-12-31 |
Bristol-Myers Squibb Company |
Protitelesa proti z glukortikoidom induciranim receptorjem za faktor nekroze tumorja(GITR) in njihova uporaba
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
EP3172235A2
(en)
|
2014-07-25 |
2017-05-31 |
Cytomx Therapeutics Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
TW201609811A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
具有增強之組織分布之雙特異性單鏈抗體構築體
|
GB201414730D0
(en)
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
WO2016032334A1
(en)
|
2014-08-28 |
2016-03-03 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
|
CN105471609B
(zh)
|
2014-09-05 |
2019-04-05 |
华为技术有限公司 |
一种用于配置业务的方法和装置
|
EA037647B1
(ru)
|
2014-09-05 |
2021-04-27 |
Янссен Фармацевтика Нв |
Агенты, связывающиеся с cd123, и виды их применения
|
EP3191517B1
(en)
|
2014-09-10 |
2020-11-04 |
Innate Pharma |
Cross reactive siglec antibodies
|
HUE044704T2
(hu)
|
2014-09-16 |
2019-11-28 |
Innate Pharma |
Kezelési rendek anti-NKG2A ellenanyagok alkalmazásával
|
US20170247476A1
(en)
|
2014-09-25 |
2017-08-31 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
CN107109368A
(zh)
|
2014-10-07 |
2017-08-29 |
塞勒克提斯公司 |
用于调节car诱导的免疫细胞活性的方法
|
GB201419579D0
(en)
|
2014-11-03 |
2014-12-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
CN107108556B
(zh)
|
2014-11-03 |
2020-09-29 |
艾欧米制药有限公司 |
药用化合物
|
JP6755866B2
(ja)
|
2014-11-10 |
2020-09-16 |
メディミューン リミテッド |
Cd73特異的結合分子及びその使用
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
US11001625B2
(en)
|
2014-12-10 |
2021-05-11 |
Tufts University |
VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
EP3253796A1
(en)
|
2015-02-03 |
2017-12-13 |
Université Catholique de Louvain |
Anti-garp protein and uses thereof
|
CA2975655C
(en)
|
2015-02-05 |
2023-09-19 |
Janssen Vaccines & Prevention B.V. |
Binding molecules directed against influenza hemagglutinin and uses thereof
|
CA2976360A1
(en)
|
2015-02-11 |
2016-08-18 |
Aptevo Research And Development Llc |
Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
|
DK3259597T3
(da)
|
2015-02-19 |
2022-05-09 |
Compugen Ltd |
Pvrig-polypeptider og fremgangsmåder til behandling
|
PT3295951T
(pt)
|
2015-02-19 |
2020-07-21 |
Compugen Ltd |
Anticorpos anti-pvrig e métodos de utilização
|
KR102013512B1
(ko)
|
2015-03-17 |
2019-08-22 |
화이자 인코포레이티드 |
신규 3-인돌 치환 유도체, 제약 조성물 및 사용 방법
|
BR112017022852A2
(pt)
|
2015-04-22 |
2018-07-17 |
Agbiome Inc |
polipeptídeo recombinante com atividade pesticida, composição, molécula de ácido nucleico recombinante, ácido nucleico recombinante, célula hospedeira, construto de dna, vetor, método para controlar uma população de pragas, método para produzir um polipeptídeo, planta, semente transgênica, método para proteger uma planta e método para aumentar o rendimento em uma planta
|
JP2018520642A
(ja)
|
2015-05-01 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
マスク抗cd3抗体及びその使用方法
|
EP3291836A4
(en)
|
2015-05-06 |
2018-11-14 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
JP6841754B2
(ja)
|
2015-05-13 |
2021-03-10 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
EP4345112A3
(en)
*
|
2015-05-13 |
2024-06-26 |
Ablynx N.V. |
T cell recruiting polypeptides based on cd3 reactivity
|
WO2016181348A1
(en)
|
2015-05-14 |
2016-11-17 |
Pfizer Inc. |
Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
|
IL274151B
(en)
*
|
2015-05-21 |
2022-07-01 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
JP6867302B2
(ja)
|
2015-05-21 |
2021-04-28 |
フル スペクトラム ジェネティクス, インコーポレイテッド |
タンパク質の特徴を改善する方法
|
MA46313A
(fr)
|
2015-06-03 |
2021-04-28 |
Agbiome Inc |
Gènes pesticides et leurs procédés d'utilisation
|
WO2016210447A1
(en)
|
2015-06-26 |
2016-12-29 |
University Of Southern California |
Masking chimeric antigen receptor t cells for tumor-specific activation
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
WO2017010874A1
(en)
*
|
2015-07-10 |
2017-01-19 |
Merus N.V. |
Human cd3 binding antibody
|
CA2991799A1
(en)
*
|
2015-07-15 |
2017-01-19 |
Zymeworks Inc. |
Drug-conjugated bi-specific antigen-binding constructs
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI793062B
(zh)
*
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
EA036975B1
(ru)
|
2015-08-03 |
2021-01-21 |
Энгмаб Сарл |
Моноклональные антитела против bcma
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
EP3334733A1
(en)
|
2015-08-10 |
2018-06-20 |
Pfizer Inc |
3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
WO2017025698A1
(en)
|
2015-08-11 |
2017-02-16 |
Queen Mary University Of London |
Bispecific, cleavable antibodies
|
AU2016308567B2
(en)
|
2015-08-17 |
2022-10-27 |
Janssen Biotech, Inc. |
Anti-BCMA antibodies, bispecific antigen binding molecules that bind BCMA and CD3, and uses thereof
|
CN106519037B
(zh)
|
2015-09-11 |
2019-07-23 |
科济生物医药(上海)有限公司 |
可活化的嵌合受体
|
IL302932A
(en)
|
2015-09-24 |
2023-07-01 |
Daiichi Sankyo Co Ltd |
Antibodies against GARP, nucleotides encoding them, and vectors, cells and preparations containing them, methods for their preparation and uses thereof
|
CN116003596A
(zh)
|
2015-10-29 |
2023-04-25 |
艾利妥 |
抗siglec-9抗体及其使用方法
|
EP3370743A4
(en)
|
2015-11-05 |
2019-04-24 |
City of Hope |
METHODS OF PREPARING LYMPHOCYTES FOR ADOPTIVE TRANSFER THERAPY OF T-CELLS
|
ES2873846T3
(es)
|
2015-11-19 |
2021-11-04 |
Revitope Ltd |
Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas
|
AU2016355320B2
(en)
|
2015-11-19 |
2023-12-07 |
Genentech, Inc. |
Methods of treating cancer using B-RAF inhibitors and immune checkpoint inhibitors
|
MX2018006767A
(es)
|
2015-12-04 |
2019-03-14 |
Novartis Ag |
Composiciones y metodos para oncologia inmunologica.
|
WO2017123745A1
(en)
|
2016-01-12 |
2017-07-20 |
Palleon Pharma Inc. |
Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
|
US9624185B1
(en)
|
2016-01-20 |
2017-04-18 |
Yong Xu |
Method for preparing IDO inhibitor epacadostat
|
EP3411380A4
(en)
|
2016-02-03 |
2020-01-22 |
Youhealth Biotech, Limited |
COMPOUNDS FOR THE TREATMENT OF EYE DISORDERS OR DISEASES
|
CN105968204B
(zh)
|
2016-02-03 |
2020-01-21 |
中国人民解放军第三军医大学第一附属医院 |
一种抗前列腺特异性膜抗原的单域重链抗体
|
CR20180420A
(es)
|
2016-02-03 |
2018-12-05 |
Amgen Inc |
Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t
|
CN105968201A
(zh)
|
2016-02-03 |
2016-09-28 |
南昌大学 |
针对前列腺特异性膜抗原的单域重链抗体
|
JP7195927B2
(ja)
|
2016-03-08 |
2022-12-26 |
武田薬品工業株式会社 |
誘導性結合タンパク質及びその使用方法
|
WO2017157305A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
KR102444614B1
(ko)
|
2016-03-22 |
2022-09-21 |
에프. 호프만-라 로슈 아게 |
프로테아제-활성화된 t 세포 이중특이적 분자
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス,インク. |
単一ドメイン血清アルブミン結合タンパク質
|
MX2018014227A
(es)
|
2016-05-20 |
2019-08-22 |
Harpoon Therapeutics Inc |
Proteinas de union de cadena unica de fragmento variable cd3.
|
US20170349660A1
(en)
|
2016-06-01 |
2017-12-07 |
Xencor. Inc. |
Bispecific antibodies that bind cd123 and cd3
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
WO2018017864A2
(en)
|
2016-07-20 |
2018-01-25 |
Oncomed Pharmaceuticals, Inc. |
Pvrig-binding agents and uses thereof
|
JP2019528051A
(ja)
|
2016-07-21 |
2019-10-10 |
ディヴェロップメント センター フォー バイオテクノロジー |
修飾抗原結合Fab断片及びこれを含む抗原結合分子
|
JP7109789B2
(ja)
|
2016-08-02 |
2022-08-01 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法
|
EA201990296A1
(ru)
|
2016-08-05 |
2019-08-30 |
Аллакос, Инк. |
Антитела против siglec-7 для лечения рака
|
JP7100018B2
(ja)
|
2016-08-08 |
2022-07-12 |
アセチロン ファーマシューティカルズ インコーポレイテッド |
ヒストンデアセチラーゼ6阻害剤及びcd20阻害抗体の薬学的組み合わせならびにその使用
|
SI3347379T1
(sl)
|
2016-08-17 |
2020-04-30 |
Compugen Ltd. |
ANTI-TIGIT protitelesa, ANTI-PVRIG protitelesa in njihove kombinacije
|
US20190218294A1
(en)
|
2016-09-09 |
2019-07-18 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
JP7217970B2
(ja)
|
2016-10-07 |
2023-02-06 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を用いてt細胞受容体をリプログラミングするための組成物及び方法
|
WO2018071777A1
(en)
|
2016-10-14 |
2018-04-19 |
Harpoon Therapeutics, Inc. |
Innate immune cell trispecific binding proteins and methods of use
|
WO2018075359A1
(en)
|
2016-10-18 |
2018-04-26 |
Boger Henry William |
Wireless power transfer for process control
|
EP3535586A4
(en)
|
2016-11-01 |
2020-08-05 |
AnaptysBio, Inc. |
ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGUE LOBULIN AND MUCIN PROTEIN 3 (TIM-3)
|
EP4295918A3
(en)
|
2016-11-02 |
2024-03-20 |
Bristol-Myers Squibb Company |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
EA201991168A1
(ru)
|
2016-11-23 |
2019-12-30 |
Харпун Терапьютикс, Инк. |
Белок, связывающий простатический специфический мембранный антиген
|
KR20190087539A
(ko)
|
2016-11-23 |
2019-07-24 |
하푼 테라퓨틱스, 인크. |
Psma 표적화 삼중특이성 단백질 및 사용 방법
|
JOP20190133A1
(ar)
|
2016-12-08 |
2019-06-02 |
Innovent Biologics Suzhou Co Ltd |
أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
|
US20200024352A1
(en)
|
2016-12-08 |
2020-01-23 |
Eli Lilly And Company |
Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
|
US11180554B2
(en)
|
2016-12-13 |
2021-11-23 |
Astellas Pharma Inc. |
Anti-human CD73 antibody
|
WO2018115859A1
(en)
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
WO2018136725A1
(en)
|
2017-01-19 |
2018-07-26 |
Harpoon Therapeutics, Inc. |
Innate immune cell inducible binding proteins and methods of use
|
CN108341872B
(zh)
|
2017-01-23 |
2020-05-19 |
科济生物医药(上海)有限公司 |
靶向bcma的抗体及其应用
|
WO2018160671A1
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Targeted checkpoint inhibitors and methods of use
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
WO2018165619A1
(en)
|
2017-03-09 |
2018-09-13 |
Cytomx Therapeutics, Inc. |
Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
|
WO2018183366A1
(en)
|
2017-03-28 |
2018-10-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
WO2018204717A1
(en)
|
2017-05-03 |
2018-11-08 |
Harpoon Therapeutics, Inc. |
Compositions and methods for adoptive cell therapies
|
CN115028727A
(zh)
|
2017-05-12 |
2022-09-09 |
哈普恩治疗公司 |
靶向msln的三特异性蛋白质及使用方法
|
US20200270362A1
(en)
|
2017-05-12 |
2020-08-27 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
BR112019023855B1
(pt)
|
2017-05-12 |
2021-11-30 |
Harpoon Therapeutics, Inc |
Proteínas de ligação à mesotelina
|
PE20191846A1
(es)
|
2017-06-02 |
2019-12-31 |
Pfizer |
Anticuerpos especificos para flt3 y sus usos
|
US20210079057A1
(en)
|
2017-06-13 |
2021-03-18 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
CA3066514A1
(en)
|
2017-07-10 |
2019-01-17 |
Innate Pharma |
Siglec-9-neutralizing antibodies
|
US11447545B2
(en)
|
2017-07-10 |
2022-09-20 |
Innate Pharma |
Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
|
AU2018311503C1
(en)
|
2017-08-01 |
2023-11-30 |
Medimmune, Llc |
BCMA monoclonal antibody-drug conjugate
|
JP2019052753A
(ja)
|
2017-09-15 |
2019-04-04 |
日本電産株式会社 |
変速機及びアクチュエータ
|
CN111630070A
(zh)
|
2017-10-13 |
2020-09-04 |
哈普恩治疗公司 |
三特异性蛋白质及使用方法
|
AU2018346955A1
(en)
|
2017-10-13 |
2020-04-30 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
WO2019136305A1
(en)
|
2018-01-04 |
2019-07-11 |
Neumedicines Inc. |
Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
|
WO2019166650A1
(en)
|
2018-03-02 |
2019-09-06 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
CA3100327A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
WO2019222282A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Conditionally activated binding protein comprising a sterically occluded target binding domain
|
US20210284728A1
(en)
|
2018-05-14 |
2021-09-16 |
Harpoon Therapeutics, Inc. |
Dual binding moiety
|
JP7398396B2
(ja)
|
2018-06-01 |
2023-12-14 |
ノバルティス アーゲー |
Bcmaに対する結合分子及びその使用
|
US20210230242A1
(en)
|
2018-06-18 |
2021-07-29 |
Anwita Biosciences, Inc. |
Cytokine fusion proteins and uses thereof
|
AU2019337974A1
(en)
|
2018-09-11 |
2021-04-08 |
iTeos Belgium SA |
Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
|
US20220017626A1
(en)
|
2018-09-21 |
2022-01-20 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
WO2020061526A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Conditionally activated target-binding molecules
|
WO2020060593A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Conditionally active receptors
|
CA3114038A1
(en)
|
2018-09-25 |
2020-04-02 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
US20220000872A1
(en)
|
2018-10-31 |
2022-01-06 |
Oncotracker, Inc. |
Method of enhancing immune-based therapy
|
CA3117978A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
CN109593786A
(zh)
|
2019-01-09 |
2019-04-09 |
上海怡豪生物科技有限公司 |
联合EpCAM和MSLN单链抗体的双靶点CAR载体及其构建方法和在乳腺癌应用
|
JP2022524337A
(ja)
|
2019-03-05 |
2022-05-02 |
武田薬品工業株式会社 |
腫瘍抗原を標的とするfc領域及び部分を含有する条件的に活性化された結合タンパク質
|
SG11202112637TA
(en)
|
2019-05-14 |
2021-12-30 |
Harpoon Therapeutics Inc |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
JP2022536511A
(ja)
|
2019-06-13 |
2022-08-17 |
シートムエックス セラピューティクス,インコーポレイテッド |
癌の処置のための併用療法での活性化可能抗pdl1抗体および抗ctla-4抗体の使用
|
CN114286828A
(zh)
|
2019-06-24 |
2022-04-05 |
诺华股份有限公司 |
针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
|
CR20210687A
(es)
|
2019-06-25 |
2022-03-03 |
Gilead Sciences Inc |
PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
|
WO2021097060A1
(en)
|
2019-11-13 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
Pro immune modulating molecule comprising a clustering moiety
|
CA3170833A1
(en)
|
2020-02-21 |
2021-08-26 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
WO2021231434A1
(en)
|
2020-05-12 |
2021-11-18 |
Harpoon Therapeutics, Inc. |
Psma targeting tritacs and methods of use
|
EP4192489A2
(en)
|
2020-08-05 |
2023-06-14 |
Synthekine, Inc. |
Il2rb binding molecules and methods of use
|
WO2022032040A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il2rb/il2rg synthetic cytokines
|
WO2022098909A1
(en)
|
2020-11-06 |
2022-05-12 |
Harpoon Therapeutics, Inc. |
Epcam targeting trispecific protein for treatment of cancer
|
WO2022212732A1
(en)
|
2021-04-01 |
2022-10-06 |
Harpoon Therapeutics, Inc. |
Psma targeting tritacs and methods of use
|
CA3220884A1
(en)
|
2021-06-03 |
2022-12-08 |
Holger Wesche |
Dll3 targeting trispecific proteins and methods of use
|
WO2022256498A1
(en)
|
2021-06-03 |
2022-12-08 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
JP2024520727A
(ja)
|
2021-06-03 |
2024-05-24 |
ハープーン セラピューティクス,インク. |
Bcma標的化三重特異性タンパク質およびその使用
|
WO2022272033A2
(en)
|
2021-06-25 |
2022-12-29 |
Harpoon Therapeutics, Inc. |
Extended-release immune cell engaging proteins and methods of treatment
|
WO2023064945A2
(en)
|
2021-10-15 |
2023-04-20 |
Harpoon Therapeutics, Inc. |
Conditional activation of immunoglobulin molecules
|